Last reviewed · How we verify

NCT07099911: NMES-SCI

Neuromuscular Electrical Stimulation and Glucose Control in Spinal Cord Injury

Recruiting now NA Last updated 7 August 2025
What this trial tests

NA trial testing NMES in Spinal Cord Injury in 20 participants. Currently enrolling.

Timeline
8 August 2025
Primary endpoint
1 September 2026
1 September 2027

Quick facts

Lead sponsorUniversity of Bath
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposebasic science
Enrollment20
Start date8 August 2025
Primary completion1 September 2026
Estimated completion1 September 2027
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Bath

Who can join

18 and older, any sex, with Spinal Cord Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Overall aim: To identify the impact and acceptability of a novel method of neuromuscular electrical stimulation (NMES) for improving glucose control using a dual stable isotope tracer OGTT in individuals with spinal cord injury (SCI). Objective 1: 1. To establish the extent to which an acute bout of NMES improves health-related measures of glucose control, compared to a SHAM control trial. 2. To identify the relative magnitude of effect, compared to non-injured control participants (CON). Hypotheses: 1. NMES will be more effective at improving glucose control by increasing peripheral glucose uptake, relative to SHAM condition. 2. The effect will be greater in individuals with SCI compared to non-injured control participants. Objective 2: To investigate the real-world feasibility of NMES as a therapeutic intervention, participants with SCI will be given instructions for 2-weeks of at-home use. In-depth interviews will be conducted to evaluate acceptability and identify areas that could be adapted to effectively implement NMES in a future trial. Participants will complete two experimental trials in a randomised crossover fashion separated by 7 days which will consist of either a sham control (SHAM) or an acute bout of NMES during a 3-h oral glucose tolerance test (OGTT). Following the experimental trial days, participants with SCI will take home a NMES device and will be given instructions for 2-weeks of at-home NMES use (Figure 1) to assess acceptability and feasibility.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of NMES

Trials testing the same drug.

Other recruiting trials for Spinal Cord Injury

Currently open trials in the same condition.

Other University of Bath trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07099911.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing